14 results about "Deferasirox" patented technology

The invention relates to the technical field of concentration, in particular to a concentration device for preparing deferasirox raw materials, which comprises a box body and the like, a liquid storage area and a concentration area are vertically arranged in the box body, the liquid storage area is communicated with the concentration area through at least one pipeline, at least one liquid inlet is arranged on the pipeline, and a vacuum pump is communicated with the outer side wall of the concentration area. A second temperature control rod is arranged in the concentration area, at least one concentration barrel is mounted in the concentration area, and the concentration barrel is communicated with the pipeline. The device is provided with the box body, the concentration cylinders, the first spiral blades and other parts, the boiling point of a solution is reduced through a vacuum environment, the multiple concentration cylinders are arranged for high-temperature concentration, the original same amount of solution is divided into multiple groups for high-temperature concentration, the high-temperature concentration time is shortened, and part of active ingredients are prevented from being damaged by heating; then low-temperature concentration is conducted in the final stage of concentration, it is ensured that thermosensitive components in the solution are kept stable by further lowering the temperature, and finally the high-concentration deferasirox raw material solution is obtained.

Metal chelation compounds and associated coordination complexes are provided. In one aspect, this disclosure provides for a metal chelation compound, the compound having the general structure: D-L-T, wherein D is deferasirox or a derivative thereof, T is triapine or a derivative thereof, and L is a linking group and is a bond, C1-C10 alkyl, C2-C10 alkenyl, or —(C0-C3 alkyl)-R—(C0-C3 alkyl)-, wherein R is aryl, cycloalkyl, or polyethylene glycol.

The invention relates to deferasirox as a human xanthine oxidase inhibitor and application thereof. Specifically, the invention provides application of deferasirox or pharmaceutically acceptable salts, esters, isomers, solvates or prodrugs thereof in preparation of drugs for treating or preventing diseases or symptoms benefited from reduction or inhibition of xanthine oxidase expression or activity, and application of deferasirox or pharmaceutically acceptable salts, esters, isomers, solvates or prodrugs thereof in preparation of drugs for treating or preventing diseases or symptoms benefited from reduction or inhibition of xanthine oxidase expression or activity. Or application in preparation of drugs for treating or preventing diseases or symptoms benefited from inhibition of uric acid production and / or reduction of uric acid content.

The invention relates to a pharmaceutical dosage form filled with formulations for once-a-day oral administration of deferiprone and deferasirox. Both formulations are in form of coated pellets or coated minitablets. The invention is directed to the claimed pharmaceutical dosage form for use in the treatment of diseases which cause an overload of iron.

The invention discloses application of deferasirox in preparation of a medicine for preventing ventricular remodeling after acute myocardial infarction, and relates to the technical field of medicines, in particular to application of deferasirox in preparation of a medicine for preventing ventricular remodeling after acute myocardial infarction. The medicine plays a role in inhibiting ferroptosis and inflammatory reaction of myocardial cells so as to prevent ventricular remodeling after acute myocardial infarction; deerasirox plays an iron chelation role and an anti-oxidative stress injury role in the medicine so as to inhibit ferroptosis and inflammatory response of myocardial cells; the inhibition effect of the medicine on myocardial cell ferroptosis is that GPX4 protein is up-regulated; the dosage of deferasirox in the medicine is 30 mg / Kg every day; the deferasirox can prevent ventricular remodeling after myocardial infarction of mice by inhibiting ferroptosis and inflammatory response, including improvement of cardiac function indexes and reduction of myocardial infarction area, and a new idea and a new scheme are provided for clinical prevention of ventricular remodeling after acute myocardial infarction.

The invention relates to the technical field of medicines, in particular to application of a pharmaceutical composition in preparation of a medicine for treating thalassemia. The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from the following components in parts by mass: 2 to 5 parts of pravastatin sodium, 1 to 2 parts of roteciterp, 7 to 11 parts of deferasirox, 7 to 11 parts of morroniside and 30 to 40 parts of phellinus igniarius general flavone extract. The pharmaceutical composition provided by the invention shows multiple clinical beneficial effects in treatment of thalassemia. In the aspect of curative effect, the composition can significantly increase the number of peripheral red blood cells, the content of hemoglobin and the hematocrit of the peripheral blood of a patient and effectively reduce the variable coefficient of the volume of the red blood cells, which indicates that the composition not only can improve the anemia state, but also can improve the stability of the quality of the red blood cells. Besides, the traditional Chinese medicine composition can obviously relieve spleen enlargement and iron overload degree and reduce the iron deposition level of the liver and the spleen, so that the traditional Chinese medicine composition has a positive effect in the aspects of relieving hemolysis related complications and organ iron toxicity.

To provide a novel target for myocardial ischemia-reperfusion injury and a therapeutic agent therefor.SOLUTION: A therapeutic agent for myocardial ischemia-reperfusion injury comprising deferasirox is provided. The deferasirox may inhibit ferroptosis. The therapeutic agent for myocardial ischemia-reperfusion injury may further comprise cyclosporin A. The therapeutic agent for myocardial ischemia-reperfusion injury may be applied so as to be administered after the onset of myocardial infarction and prior to reperfusion after ischemia.SELECTED DRAWING: Figure 1

The invention discloses a deferasirox derivative, a nuclide marker as well as a preparation method and application of the deferasirox derivative. The deferasirox derivative is formed by connecting deferasirox residues, a linker and a marking group in a specific chemical form. The invention also provides a nuclide marker based on the compound structure. The compound and the nuclide marker can be enriched in inflammation or tumor focus tissues, especially can be specifically recognized by bacteria, and can accurately diagnose and locate early bacterial infection. The invention also provides an application of the nuclide marker in distinguishing bacterial infection and aseptic inflammation in living animals, and the nuclide marker has the advantages of simple and easily available marker, good stability, high specificity and the like, and is suitable for industrial production and clinical popularization.

The invention relates to the technical field of nano materials, and discloses a nano preparation as well as a preparation method and application thereof. The nano preparation contains a phospholipid compound, an inhibitor A and an inhibitor B, the inhibitor A is selected from at least one of rapamycin, fluconazole, amphotericin B and caspofungin, and the inhibitor B is selected from at least one of deferasirox, deferoxamine, deferoxone, dimercaptosuccinic acid and penicillamine. The nano preparation has a good bacteriostatic and bactericidal effect on biphasic fungi, has a good treatment effect on systemic infection, and can weaken the toxic and side effects of drugs.

The present application relates to the technical field of concentration, and particularly relates to a concentration device for preparing deferasirox raw material, which comprises a box and other components, a liquid storage area and a concentration area are arranged in the box in an up-down mode, the liquid storage area and the concentration area are connected through at least one pipeline, at least one liquid inlet is arranged on the pipeline, a vacuum pump is connected to the outer wall of the concentration area, a second temperature control rod is arranged in the concentration area, at least one concentration cylinder is arranged in the concentration area, and the concentration cylinder is connected with the pipeline. The concentration device is provided with a box, a concentration cylinder and a first spiral blade, the boiling point of the solution is reduced through a vacuum environment, multiple concentration cylinders are arranged for high-temperature concentration, the originally equal amount of solution is divided into multiple groups for high-temperature concentration, the time of high-temperature concentration is shortened, partial active components are prevented from being damaged by heat, then low-temperature concentration is adopted in the last stage of concentration, the temperature is further reduced to ensure that the heat-sensitive components in the solution remain stable, and finally high-concentration deferasirox raw material solution is obtained.

The present invention relates to the field of biomedicine, and more specifically to the use of the novel iron chelator CN128 / deferasirox (DFX) in the prevention and treatment of nonalcoholic steatohepatitis. CN128 or deferasirox can significantly reduce liver damage, steatosis, and hepatocellular ballooning in MCD-induced nonalcoholic steatohepatitis.

This invention provides a method for synthesizing deferasirox. The method involves reacting starting material A with hydrochloric acid-ethanol solution in solvent a to generate intermediate B; intermediate B reacts with salicylyl chloride and pyridine in solvent b to generate intermediate C; and intermediate C reacts with p-hydrazide benzoate in solvent c to generate deferasirox. This method is simple to operate, has mild reaction conditions, high yield, low cost, is environmentally friendly, and is suitable for large-scale industrial production of deferasirox.